Potential of chemo-immunotherapy and radioimmunotherapy in relapsed primary central nervous system (CNS) lymphoma

Autor:	Deborah A. Ryan, Csanad Varallyay, Robert W. Nance, Rose Marie Tyson, Nancy D. Doolittle, Richard Belanger, Cynthia Lacy, Kristoph Jahnke, Edward A. Neuwelt, Marianne Haluska, Nancy A. Hedrick
Rok vydání:	2007
Předmět:	Adult Male Oncology Cancer Research medicine.medical_specialty medicine.medical_treatment Ibritumomab tiuxetan Carboplatin chemistry.chemical_compound Internal medicine medicine Humans Yttrium Radioisotopes Aged Brain Neoplasms business.industry Lymphoma Non-Hodgkin Indium Radioisotopes Primary central nervous system lymphoma Antibodies Monoclonal Hematology Middle Aged Radioimmunotherapy medicine.disease Combined Modality Therapy Lymphoma Methotrexate chemistry Blood-Brain Barrier Monoclonal Female Rituximab business Nuclear medicine medicine.drug
Zdroj:	Leukemia & Lymphoma. 48:1712-1720
ISSN:	1029-2403 1042-8194
Popis:	Five patients with relapsed PCNSL were given chemo-immunotherapy (rituximab followed by carboplatin and methotrexate) with osmotic blood-brain barrier (BBB) opening. Four patients achieved CR and one patient had stable disease. Two patients (2/5) had durable responses (survival: 230+, 122+, 82, 42, 38 weeks). One patient later received Indium-111-ibritumomab tiuxetan and Yttrium-90-ibritumomab tiuxetan intravenous, without BBB opening. There was good uptake of Indium-111 ibritumomab tiuxetan in tumor on SPECT scan after 48 h. Estimated radiation doses to brain around and distant from tumor were within safe limits. After Ytrium-90 ibritumomab tiuxetan there was CR in enhancing tumor where the BBB was leaky, but lesions occurred in other brain regions, where the BBB was intact during Yttrium-90 ibritumomab tiuxetan infusion. Imaging and dosimetry with Indium-111 ibritumomab tiuxetan and efficacy with Yttrium-90 ibritumomab tiuxetan suggest the need for future enhanced CNS delivery when using monoclonal or radiolabeled antibodies, as intravenous delivery alone may provide modest clinical benefit due to limited BBB permeability.
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6bcfae9f424705d3fee80b52fcb62f6d https://doi.org/10.1080/10428190701493902 Zobrazit plný text záznamu Plný text ve formátu PDF Plný text ve formátu HTML
Nepřihlášeným uživatelům se plný text nezobrazuje	K zobrazení výsledku je třeba se přihlásit.